Cargando…
MMP9 Expression Correlates With Cisplatin Resistance in Small Cell Lung Cancer Patients
Background: Cisplatin is the basis of the primary treatment for SCLC chemotherapy. However, the limited objective response rate and definite drug resistance greatly restrict the clinical potential and therapeutic benefits of cisplatin use. Therefore, it is essential to identify biomarkers that can d...
Autores principales: | Wu, Longqiu, Wang, Xiangcai, He, Xin, Li, Qiang, Hua, Qian, Liu, Rongrong, Qiu, Zhengang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9010875/ https://www.ncbi.nlm.nih.gov/pubmed/35431936 http://dx.doi.org/10.3389/fphar.2022.868203 |
Ejemplares similares
-
Fatty Acid Metabolic Signaling Pathway Alternation Predict Prognosis of Immune Checkpoint Inhibitors in Glioblastoma
por: Liu, Rongrong, et al.
Publicado: (2022) -
Effect of Wenxia Changfu Formula Combined With Cisplatin Reversing Non-Small Cell Lung Cancer Cell Adhesion-Mediated Drug Resistance
por: Wang, Meng-Ran, et al.
Publicado: (2020) -
Identification of Mutations Related to Cisplatin-Resistance and Prognosis of Patients With Lung Adenocarcinoma
por: Li, Rui, et al.
Publicado: (2020) -
Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and literature review
por: Wu, Longqiu, et al.
Publicado: (2021) -
Piperlongumine Inhibits Akt Phosphorylation to Reverse Resistance to Cisplatin in Human Non-Small Cell Lung Cancer Cells via ROS Regulation
por: Zhang, Chao, et al.
Publicado: (2019)